Skip to main content
. 2022 Oct 10;13:5959. doi: 10.1038/s41467-022-33555-8

Fig. 4. S-TRAC trial samples classification according to the TCGA KIRC molecular subtypes and S-TRAC trial samples immune cell-type–specific gene expression profiles.

Fig. 4

Kaplan–Meier plots of DFS stratified according to TCGA molecular subtype classification for a the overall population and b sunitinib treatment arm. c Cell types significantly associated with DFS in S-TRAC trial samples. Longer DFS (red), shorter DFS (blue), and non-significant (white). Each cell type score (xCell) was stratified by >median or ≤median for the overall cohort, sunitinib arm, or placebo arm. The likelihood ratio was filtered for p < 0.05 and the log2(HR) was clustered in a heatmap. Non-significant cell types for both arms and overall cohort are not shown. For significant and non-significant cell types for both arms and overall cohort, xCell scores are provided in the file Figure4c_celltypes_DFS/xCell.complete.tsv CI confidence interval, DFS disease-free survival, HR hazard ratio, NE not estimable, TCGA The Cancer Genome Atlas.